{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injection+of+EBV+Specific+CTLs", "query": { "intervention": "Injection of EBV Specific CTLs" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injection+of+EBV+Specific+CTLs&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T12:12:02.032Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00058812", "title": "Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epstein-Barr Virus Infections" ], "interventions": [ { "name": "EBV specific T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 69, "start_date": "1993-05", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2015-01-29", "last_synced_at": "2026-09-08T12:12:02.032Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058812" }, { "nct_id": "NCT00082225", "title": "LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "CD45 antibodies", "type": "BIOLOGICAL" }, { "name": "EBV specific T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 4, "start_date": "2003-10", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-09-08T12:12:02.032Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082225" }, { "nct_id": "NCT01447056", "title": "Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin Lymphoma", "Non-Hodgkin Lymphoma", "Lymphoproliferative Disorder", "Nasopharyngeal Carcinoma", "Leiomyosarcoma", "Severe Chronic Active EBV (SCAEBV)" ], "interventions": [ { "name": "LMP specific T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 37, "start_date": "2012-02", "completion_date": "2020-01-22", "has_results": false, "last_update_posted_date": "2020-02-07", "last_synced_at": "2026-09-08T12:12:02.032Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01447056" }, { "nct_id": "NCT00062868", "title": "LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin Disease", "Non Hodgkin Lymphoma", "Lymphoepithelioma", "Leiomyosarcoma" ], "interventions": [ { "name": "LMP1/2 CTLs (ALCI - Group A)", "type": "BIOLOGICAL" }, { "name": "LMP1/2 CTLs (ALCI - Group B)", "type": "BIOLOGICAL" }, { "name": "LMP1/2 CTLs (ALCI - Group C)", "type": "BIOLOGICAL" }, { "name": "LMP2 CTLs (ALSCER - Group A)", "type": "BIOLOGICAL" }, { "name": "LMP2 CTLs (ALSCER - Group B)", "type": "BIOLOGICAL" }, { "name": "LMP2 CTLs (ALSCER - Group C)", "type": "BIOLOGICAL" }, { "name": "LMP1/2 CTLs (ALCI - Expansion - Group A)", "type": "BIOLOGICAL" }, { "name": "LMP1/2 CTLs (ALCI - Expansion Group B)", "type": "BIOLOGICAL" }, { "name": "LMP1/2 CTLs (ALCI - Expansion Group C)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 74, "start_date": "2003-09", "completion_date": "2020-04", "has_results": true, "last_update_posted_date": "2020-06-09", "last_synced_at": "2026-09-08T12:12:02.032Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00062868" }, { "nct_id": "NCT01192464", "title": "EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin's Lymphoma", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "autologous CAR.CD30 EBV specific-CTLs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 18, "start_date": "2011-05-10", "completion_date": "2033-10", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-09-08T12:12:02.032Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01192464" }, { "nct_id": "NCT00516087", "title": "LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "Genetically modified CTLs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 23, "start_date": "2007-08", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-09-08T12:12:02.032Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00516087" }, { "nct_id": "NCT00368082", "title": "Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Hodgkin's Disease", "Relapse", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "TGFbeta resistant LMP-specific CTLs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 8, "start_date": "2006-04", "completion_date": "2031-07", "has_results": false, "last_update_posted_date": "2025-10-31", "last_synced_at": "2026-09-08T12:12:02.032Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00368082" }, { "nct_id": "NCT01555892", "title": "Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin's Disease", "Non-Hodgkin's Lymphoma", "Lymphoproliferative Disease", "Lymphoma" ], "interventions": [ { "name": "EBV-specific T cells: A", "type": "BIOLOGICAL" }, { "name": "EBV-specific T cells: B", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 136, "start_date": "2013-01-14", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-09-08T12:12:02.032Z", "location_count": 3, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01555892" }, { "nct_id": "NCT00078546", "title": "EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nasopharyngeal Cancer", "EBV Infections" ], "interventions": [ { "name": "EBV specific CTL Infusion", "type": "BIOLOGICAL" }, { "name": "Anti CD45 monoclonal antibody", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 12, "start_date": "2003-09", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2012-07-30", "last_synced_at": "2026-09-08T12:12:02.032Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00078546" }, { "nct_id": "NCT00058617", "title": "Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epstein-Barr Virus-Related Hodgkin Lymphoma", "Epstein-Barr Virus-Related Non-Hodgkin Lymphoma", "EBV Positive Plasma Cell Neoplasm" ], "interventions": [ { "name": "Injection of EBV Specific CTLs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 13, "start_date": "1996-01", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-09-08T12:12:02.032Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058617" } ] }